FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study

被引：0
|
作者：
Kumiko Umemoto
Hideaki Takahashi
Chigusa Morizane
Ikuhiro Yamada
Satoshi Shimizu
Kazuhiko Shioji
Yukio Yoshida
Masayo Motoya
Nobumasa Mizuno
Yasushi Kojima
Takeshi Terashima
Kazuhiro Uesugi
Makoto Ueno
Junji Furuse
Tetsuo Akimoto
Masafumi Ikeda
机构：
[1] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Oncology
[2] Juntendo University Graduate School of Medicine,Course of Advanced Clinical Research of Cancer
[3] Cancer Institute Hospital,Department of Gastroenterology
[4] Japanese Foundation For Cancer Research,Department of Gastroenterology
[5] Saitama Cancer Center,Department of Internal Medicine
[6] Niigata Cancer Center Hospital,Division of Gastrointestinal Oncology
[7] Shizuoka Cancer Center,Department of Gastroenterology and Hepatology
[8] Sapporo Medical University,Department of Gastroenterology
[9] Aichi Cancer Center Hospital,Department of Gastroenterology
[10] National Center for Global Health and Medicine,Department of Gastroenterology
[11] Kanazawa University Hospital,Departments of Gastroenterology
[12] National Hospital Organization Shikoku Cancer Center,Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division
[13] Kanagawa Cancer Center,Faculty of Medicine, Department of Medical Oncology
[14] Kyorin University,Department of Radiation and Oncology and Particle Therapy
[15] National Cancer Center Hospital East,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
UGT1A1 *28 or *6 polymorphism; Advanced pancreatic cancer; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：397 / 404
页数：7
相关论文
共 50 条
  • [21] UGT1A1☆6 AND UGT1A1☆28 ARE ASSOCIATED WITH IRINOTECAN-INDUCED SEVERE LEUKOPENIA IN JAPANESE PATIENTS WITH LUNG CANCER
    Fukuda, Minoru
    Okumura, Manabu
    Hisatomi, Keiko
    Suyama, Naofumi
    Iwakiri, Tomomi
    Takagi, Akinori
    Nakamura, Yoichi
    Arimori, Kazuhiko
    Kohno, Shigeru
    RESPIROLOGY, 2010, 15 : 37 - 37
  • [22] A population study on the UGT1A1*28 variant associated to irinotecan tolerance
    Roman, Ruth
    Colomer, Anna
    Erill, Nadina
    Verdú, Montse
    Ibañez, Rosa
    Cardo, Carles Cordon
    Puig, Xavier
    MODERN PATHOLOGY, 2006, 19 : 142 - 142
  • [23] Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study
    Keum, Jiyoung
    Lee, Hee Seung
    Jo, Jung Hyun
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    Bang, Seungmin
    CANCERS, 2022, 14 (05)
  • [24] The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    Toffoli, Giuseppe
    Cecchin, Erika
    Corona, Giuseppe
    Russo, Antonio
    Buonadonna, Angela
    D'Andrea, Mario
    Pasetto, Lara Maria
    Pessa, Sergio
    Errante, Domenico
    De Pangher, Vincenzo
    Giusto, Mauro
    Medici, Michele
    Gaion, Fernando
    Sandri, Paolo
    Galligioni, Enzo
    Bonura, Salvatore
    Boccalon, Massimo
    Biason, Paola
    Frustaci, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3061 - 3068
  • [25] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    Journal of Traditional Chinese Medicine, 2017, 37 (01) : 35 - 42
  • [26] UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
    Yu Sunakawa
    Wataru Ichikawa
    Ken-ichi Fujita
    Fumio Nagashima
    Hiroo Ishida
    Keishi Yamashita
    Keiko Mizuno
    Keisuke Miwa
    Kaori Kawara
    Yuko Akiyama
    Kazuhiro Araki
    Wataru Yamamoto
    Toshimichi Miya
    Masaru Narabayashi
    Yuichi Ando
    Takashi Hirose
    Shigehira Saji
    Yasutsuna Sasaki
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 279 - 284
  • [27] Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms
    Deng Bo
    Jia Liqun
    Tan Huangying
    Lou Yanni
    Li Xue
    Li Yuan
    Yu Lili
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2017, 37 (01) : 35 - 42
  • [28] UGT1A1*1/*28 and*1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
    Sunakawa, Yu
    Ichikawa, Wataru
    Fujita, Ken-ichi
    Nagashima, Fumio
    Ishida, Hiroo
    Yamashita, Keishi
    Mizuno, Keiko
    Miwa, Keisuke
    Kawara, Kaori
    Akiyama, Yuko
    Araki, Kazuhiro
    Yamamoto, Wataru
    Miya, Toshimichi
    Narabayashi, Masaru
    Ando, Yuichi
    Hirose, Takashi
    Saji, Shigehira
    Sasaki, Yasutsuna
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 279 - 284
  • [29] Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism
    Hazama, Shoichi
    Nagashima, Atsushi
    Kondo, Hiroshi
    Yoshida, Shin
    Shimizu, Ryoichi
    Araki, Atsuhiro
    Yoshino, Shigefumi
    Okayama, Naoko
    Hinoda, Yuji
    Oka, Masaaki
    CANCER SCIENCE, 2010, 101 (03) : 722 - 727
  • [30] Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28
    Tian, Chuan
    Ying, Haifeng
    Zhuang, Rongyuan
    Zhang, Xiaowei
    Lu, Hongmin
    Wang, Hui
    Wang, Shuowen
    Li, Qi
    Wang, Chungang
    Cai, Xun
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6217 - 6226
12345